Navigation Links
Protein controls blood vessel formation, offers new drug target

CHAPEL HILL After an injury, the body grows new blood vessels to repair damaged tissue. But sometimes too much growth causes problems, as when new blood vessels in the eyes leak, causing diabetic retinopathy and blindness if not treated.

A protein called CIB1 discovered by researchers at the University of North Carolina at Chapel Hill School of Medicine appears to play a major role in controlling new blood vessel growth, offering a target for drug treatments to help the body repair itself after injury and control unwanted blood vessel growth.

In the future, this knowledge may help our ability to control blood vessel growth in disease situations such as wound healing, retinal diseases and diabetes, said Leslie Parise, Ph.D., senior study author and professor and chair of biochemistry and biophysics in the UNC School of Medicine.

The results will appear in an upcoming print issue of the journal Circulation Research and were published online Nov. 1, 2007. The research was funded by the National Institutes of Health.

Parises lab first discovered the protein, called CIB1 in 1997. It was originally found in blood platelets. CIB1 keeps blood platelets from sticking together, acting as a natural anti-coagulant to prevent clots that might lead to heart attacks or strokes. But further research showed CIB1 appears in almost every cell type in the body, Parise said. For example, male mice bred without both copies of the CIB1 gene are infertile.

In the current study, Parise and her colleagues found CIB1 in the endothelial cells that line all blood vessels. These cells jump-start new blood vessel growth via a process called angiogenesis. During angiogenesis, biological signals prompt endothelial cells to release enzymes and other chemicals that allow them to move away from existing blood vessels and form new ones.

While angiogenesis plays a critical role in embryo growth, CIB1 appears to only affect blood vessel growth after injury (sometimes called pathological or adaptive angiogenesis). Mice born without copies of the CIB1 gene survive and are reasonably healthy unless injured, Parise said.

CIB1 appears to be an attractive drug target to control blood vessel growth since it does not play an essential role during fetal development but instead plays an important role in pathological forms of blood vessel growth, said first author and medical student at UNC Mohamed Zayed, Ph.D.

In experiments in mice missing CIB1 genes, the researchers found that CIB1 is critical for angiogenesis in the retina, as well as angiogenesis in hind legs. In both cases, the new blood vessel growth was prompted by ischemia, or restricted blood flow. However, clinicians treating retinal disease need to restrict blood vessel growth in the eyes, while patients with restricted blood flow in their limbs need to grow need blood vessels. Therefore, CIB1 could be a target for both pro- and anti-angiogenic drug therapies.

Parise notes that the lab is still determining the exact role CIB1 plays in angiogenesis. We think its involved in the chemical pathways that control blood vessel growth, such as signal transduction events, she said. It is also likely that CIB1 is one of many genes that contribute to angiogenesis during ischemia, inflammation and perhaps even tumor growth.


Contact: Les Lang
University of North Carolina at Chapel Hill

Related biology news :

1. Protein chatter linked to cancer activation
2. Scientists link fragile X tremor/ataxia syndrome to binding protein in RNA
3. Researchers identify proteins involved in new neurodegenerative syndrome
4. Low levels of key protein may indicate pancreatic cancer risk
5. Structure of 450 million year old protein reveals evolutions steps
6. Scientists retrace evolution with first atomic structure of an ancient protein
7. Specific brain protein required for nerve cell connections to form and function
8. NIH awards researcher $1.5 million new innovator grant for fruit-fly studies of prion proteins
9. Interacting protein theory awaits test from new neutron analysis tools
10. Depression, aging, and proteins made by a virus may all play role in heart disease
11. Census of protein architectures offers new view of history of life
Post Your Comments:
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
Breaking Biology Technology: